Commercial adoption of the LIBERTY System by sites that participated in the clinical trial serves as a strong validation of the value it brings ...
Microbot Medical designed its Liberty disposable surgical robotic system to overcome adoption barriers in robot-assisted ...
Representing a significant advancement in healthcare, endovascular procedures performed inside blood vessels embody the intersection of medicine and technology. By addressing critical conditions such ...
BRAINTREE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (MBOT) today announced it has entered into an agreement with Emory University, which will allow the parties to evaluate and ...
HINGHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (MBOT), developer of the innovative LIBERTY ® Endovascular Robotic System, announced its participation in the inaugural ...
HINGHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY ® Endovascular Robotic System, announced that Harel Gadot, ...
Microbot Medical Inc. MBOT recently announced that it has entered into an agreement with Emory University, which is likely to allow the entities to evaluate and explore the potential for future ...
Microbot Medical, a surgical robotics company, has announced the FDA approval to start its human clinical trials for the Liberty Endovascular Robotic Surgical System. The Liberty system was designed, ...
Microbot Medical has secured FDA clearance for the LIBERTY System, the first FDA-approved, single-use, remotely operated robotic system for peripheral endovascular procedures. With the clearance ...
BRAINTREE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Microbot Medical® Inc. (Nasdaq: MBOT), developer of the innovative single use LIBERTY® Endovascular Robotic System, announces that its Chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results